Breast Cancer

FDA approves adjuvant abemaciclib plus endocrine therapy for select HR+ early breast cancer

October 13, 2021

The FDA has approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of 20% or higher, as determined by an FDA-approved test.

Data aid in treatment for vulvovaginal health, sexual function after cancer

October 11, 2021

Analyzing the relationship between data from patient self-reports and clinician ratings of vulvovaginal tissue health following cancer can help provide better sexual function treatment for patients, according to a recent study.

Sacituzumab govitecan-hziy improves quality of life in patients with metastatic triple-negative breast cancer

October 06, 2021

Sacituzumab govitecan-hziy resulted in a statistically significant and clinically meaningful improvement in health-related quality of life compared with single-agent chemotherapy of physician’s choice in patients with metastatic triple-negative breast cancer.

FDA grants trastuzumab deruxtecan breakthrough therapy designation for breast cancer

October 05, 2021

The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.